PedAM
Pediatric Disease Annotations & Medicines
| Disease | myelodysplastic syndrome |
| Phenotype | C0023467|acute myeloid leukemia |
| Sentences | 19 |
| PubMedID- 26151071 | Dysplastic changes of peripheral eosinophils in acute myeloid leukemia with myelodysplastic syndrome-related features. |
| PubMedID- 26340093 | This meta-analysis, for the first time, combined myelodysplastic syndrome with acute myeloid leukemia to assess the overall risk of adult myeloid disease, and it demonstrated that cigarette smoking is associated with a significantly increased risk of adult myeloid disease. |
| PubMedID- 23362656 | Azacitidine (5-azacytidine, vidaza) is a disease-modifying agent that improves survival, reduces transfusion dependence, and reduces progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndromes. |
| PubMedID- 23137720 | Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories. |
| PubMedID- 20178141 | Dna methyltransferase inhibitors are well tolerated in outpatient settings, with azacitidine prolonging survival and decreasing time to acute myeloid leukemia progression in patients with high-risk myelodysplastic syndromes. |
| PubMedID- 22162288 | Frequencies were in detail: acute myeloid leukemia (aml): 40 of 3,798, 1.1%; myelodysplastic syndromes (mds): 6 of 3,375, 0.2%; myeloproliferative neoplasms (mpns): 5 of 1,720, 0.3%; mds/mpn: 0 of 210; and chronic myelomonocytic leukemia: 0 of 447. |
| PubMedID- 24349422 | Bard1 expression has been found to be down-regulated in samples from myelodysplastic syndrome patients (mds) with progression to acute myeloid leukemia (aml) [18]. |
| PubMedID- 23212151 | Its activation by chromosomal rearrangement induces a myelodysplastic syndrome with progression to acute myeloid leukemia of poor prognosis. |
| PubMedID- 25323649 | In patients with secondary acute myeloid leukemia (s-aml) arising from the myelodysplastic syndrome (mds), treatment outcome is unsatisfactory. |
| PubMedID- 24447728 | We assessed the outcomes of 63 patients with acute myeloid leukemia (aml) arising from myelodysplastic syndrome (mds) after hypomethylating agent failure. |
| PubMedID- 25447656 | Bpdcn typically manifests in the skin, but it can also evolve into a leukemic form or be complicated by acute myeloid leukemia, some cases with a preceding myelodysplastic syndrome (mds). |
| PubMedID- 23494725 | The above scale is poorly correlated with overall survival or transformability into acute myeloid leukemia in patients with secondary myelodysplastic syndromes who constitute a large percentage of patients [44]. |
| PubMedID- 25487075 | Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology. |
| PubMedID- 23240925 | Abrupt evolution of philadelphia chromosome-positive acute myeloid leukemia in myelodysplastic syndrome. |
| PubMedID- 21701636 | The patient developed myelodysplastic syndrome with acute myeloid leukemia (mds/aml) which was resistant to standard treatments and succumbed to the disease. |
| PubMedID- 23371544 | Secondary acute myeloid leukemia (s-aml) arising from myelodysplastic syndrome (mds) shows different clinical features from de novo aml. |
| PubMedID- 21425147 | Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. |
| PubMedID- 26171043 | Hypocellular myelodysplastic syndrome with myelofibrosis in acute myeloid leukemia transformation: a case report. |
| PubMedID- 24808792 | St-elevation myocardial infarction and myelodysplastic syndrome with acute myeloid leukemia transformation. |
Page: 1